Skip to main content
. 2023 Jul 12;3(7):1224–1236. doi: 10.1158/2767-9764.CRC-22-0329

FIGURE 2.

FIGURE 2

Treatment with PI3Ki (Omipalisib) recapitulates antitumor and immunomodulatory benefits of Uro A in PDAC. A, Schematic of PI3Ki (Omipalisib) treatment in PKT mice. B, Pancreas weight analysis of PI3Ki- or vehicle-treated PKT mice, n = 3–4 mice/group. C, Representative H&E-stained tumor sections in PI3Ki-treated mice and vehicle-treated mice. D, Cytokine array profiling of pancreatic tumor tissues harvested from PKT mice treated with PI3Ki or vehicle. Western blot analysis demonstrating decreased phosphorylation of AKT (band marked by red arrow) in murine KPC PDAC tumor cell line upon PI3Ki (0–10 μmol/L; E) and Uro A (0–75 μmol/L; F) treatment for 3 hours. G, Representative heat map showing fold change of immunomodulatory gene transcripts (qPCR analysis) associated with PI3Ki (1 μmol/L) or Uro A (25 μmol/L) treatment in KPC PDAC tumor cells for 3 hours. Individual datapoints with mean ± SEM are shown and compared by two-tailed unpaired t test; *, P < 0.05.